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Cardiotoxicity is the main dose-limiting side effect of doxorubicin in the clinic. Being a free radical producer, doxorubicin affects the
heart specifically because of its low antioxidant capacity. Among those antioxidants, catalase is present in very low levels in the heart
compared to other organs. Since catalase is an essential enzyme in detoxifying hydrogen peroxide, the aim of the present study was
to investigate the protective effect of catalase as delivered by an adenovirus vector against doxorubicin-induced cardiotoxicity in
cultured neonatal rat cardiac myocytes (NeRCaMs). 7-Monohydroxyethylrutoside (MonoHER), a potent cardioprotector currently
under clinical investigations, was included in the study as a reference. Neonatal rat cardiac myocytes were infected with different
multiplicity of infections (MOIs) of adenovirus encoding catalase (AdCat). A control infection with an adenovirus vector encoding a
nonrelated protein was included. The activity and content of catalase in infected cells were determined during 3 days postinfection.
One group of NeRCaMs was infected with AdCat before treatment with doxorubicin (0–50mM). The second and third group were
treated with doxorubicin (0–50mM) with and without 1mM monohydroxyethylrutoside (monoHER), respectively. The LDH release
and viability of treated cells were measured 24 and 48h after doxorubicin treatment. The beating rate was followed in three other
groups of cells receiving the same treatments within 3 days after doxorubicin (0–100mM) treatment. Catalase activity increased in
AdCat-infected cells, with different MOIs, starting from the second day after infection as compared to the mock-infected cells
(Po0.03). At the third day of infection, an MOI of more than 50 caused cytopathic effects, which hampered the use of higher viral
titres. With an MOI of 50, catalase activity increased 3.5-fold in AdCat-infected cells 3 days postinfection (P¼0.021) compared to
mock-infected cells. The beating rate and survival of NeRCaMs decreased in a concentration and time-dependent manner after
doxorubicin treatment (Po0.0005). This cytotoxicity was associated with an increase in the LDH release from the treated cells
(Po0.0005). The cells stopped beating 24h after treatment with 450mM doxorubicin. A 3.5-fold increase in the activity of catalase
did not protect NeRCaMs against any of the cytotoxic effects of doxorubicin on NeRCaMs. In contrast, monoHER (1mM)
significantly protected NeRCaMs against the lethal effects of doxorubicin on the survival, LDH release and the beating rate of
NeRCaMs (Po0.004) during 48h after doxorubicin treatment. This protection resulted in a prolongation of the beating of
doxorubicin-treated cells after the end of the experiment (i.e. 472h). The present study (1) illustrates that the cytotoxicity of high
MOI of AdCat (450) limited the possibility to increase catalase activity more than 3.5-fold, which was not enough to protect infected
NeRCaMs against doxorubicin-induced cardiotoxicity and (2) confirms the efficacy of monoHER as a cardioprotector. Thus, the use
of monoHER proves more suitable for the prevention of doxorubicin-induced cardiotoxicity than catalase gene transfer employing
adenovirus vectors.
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Free radicals are considered the fundamental mediators of
doxorubicin-induced cardiotoxicity. The semiquinone form, pro-
duced by the reduction of doxorubicin, interacts with molecular
oxygen yielding superoxide radicals (Goeptar et al, 1993). These
radicals are rapidly transformed either spontaneously or enzyma-
tically into hydrogen peroxide (H2O2), which is converted into
hydroxy radicals (OH
K) (Kalyanaraman et al, 1984). These highly
reactive species interact specifically with heart tissue because of its
low antioxidant content.
Several studies were conducted using exogenous metal ion
chelators and/or antioxidants like ICRF-187 and 7-monohydrox-
yethylrutoside (monoHER). These studies seemed promising in the
protection against doxorubicin-induced cardiotoxicity in vitro and
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sin vivo (Van Acker SABE et al, 1997; Van Acker FAA et al, 2000;
Koning et al, 1991) without interfering with its antitumour activity.
ICRF-187, however, showed transient leucopenia and moderate
thrombocytopenia (Koning et al, 1991) and thus amplified the
myelotoxicity of doxorubicin. The cardioprotection of monoHER
was attributed to both potent free radical scavenging and metal ion
chelating properties (Van Acker et al, 1996, 1998) of the compound
and thus compensating for the low antioxidant content of the heart
tissue (Green et al, 1990; Keizer et al, 1990; Lin et al, 1991; Takacs
et al, 1992). 7-Monohydroxyethylrutoside is under early clinical
investigation, and the search for other cardioprotectors is therefore
warranted.
Catalase is a major enzyme involved in the detoxification of
H2O2 into water and molecular oxygen (James Kang et al, 1996).
Catalase activity is high in the liver and erythrocytes, but very low
in the heart of man (Ishikawa et al, 1986) and mice (Doroshow
et al, 1980).
The use of exogenous catalase in the protection against oxidative
stress proved effective in vitro (Kirshenbaum and Singal, 1993;
Thayer, 1986), but it showed contradictory results in vivo because
of catalase instability or reduced ability to penetrate cells (Villani
et al, 1992).
The endogenous production of high levels of catalase in
transgenic mice definitely proved the efficacy of catalase in the
protection against oxidative damage as produced by ischaemia
reperfusion (IR) (Li et al, 1997) and doxorubicin (James Kang et al,
1996). These encouraging results prompted us to explore the
protective effect of catalase gene therapy against doxorubicin-
induced cardiotoxicity.
The aim of the present study was to investigate the protective
effect of adenoviral-cardiac gene transfer of catalase against the
cytotoxic effects of doxorubicin on the survival, LDH release and
the beating rate of Neonatal rat cardiac myocytes (NeRCaMs) in
vitro. The cardioprotector monoHER was used as a reference in the
present investigation.
MATERIALS AND METHODS
Adenovirus vectors
The catalase encoding adenovirus (AdCat) (Danel et al, 1998) (was
kindly provided by Dr RG Crystal, Joan and Sanford I Weill
Medical College, Cornell University) contains the cDNA of human
catalase driven by the Ad2 major late promoter (MLP). The vector
was generated by the ligation of the ClaI cut plasmid pPB369 with
the large ClaI fragment of the Ad5 E3 deletion mutant Addl327
(Erzurum et al, 1993). An adenovirus encoding nonrelated protein
was used for control infection. The adenovirus vectors were
propagated in PER C6 cells (Fallaux et al, 1998) and purified by
CsCl density gradient. The viral preparations were dialysed and
stored at –801C until use. The titre of each viral stock was
determined on 911 cells (Fallaux et al, 1996). The titres ranged
between 4–5 10
10 plaque-forming unit (p.f.u.)ml
 1. The adeno-
virus stocks were free of replication competent adenovirus (RCA)
as tested by PCR using primers flanking the AdE1A region
(Pietersen et al, 1999).
Neonatal rat cardiac myocytes isolation and culture
Hearts were aseptically removed from 16 neonatal Sprague–Dawly
rats (2–3 days old from Harlan Nederland, Horst, The Nether-
lands) after decapitation. After removal of the atria, the ventricles
were carefully dissected and washed with a buffer solution (pH
7.3), which contained NaCl (137mM), KCl (5.4mM), Na2HPO4
(0.34mM), KH2PO4 (0.44mM), D-glucose (5.56mM), 4-(2-hydro-
xyethyl)-1-piperazineethanesulphonic acid (HEPES) (20mM) and
0.02% phenol red. The dissected tissue was digested with
collagenase-deoxyribonuclease solution containing 14Uml
 1 col-
lagenase (Worthington Biochemical Corporation, Freehold, NJ,
USA), 450Uml
 1 deoxyribonuclease (DNase, Worthington Bio-
chemical Corporation), 10mM CaCl2 and 0.6mM MgCl2 (Van
Wamel et al, 2000).
The digestion mixture was incubated at 371C for 20min by
shaking in the presence of glass beads, which assists the release of
free cells from the digested tissue. The digestion step was repeated
for undissociated tissue, and the cell suspension of the two
digestion steps was pooled in one tube kept on ice. The cells were
spun down by centrifugation at 240g for 15min. The cell pellet was
suspended in preplating medium – containing Ham’s F-10 (Life
Technologies, Breda, The Netherlands), 10% fetal bovine serum
(FBS, Life Technologies) and 10% horse serum (HS, Life
Technologies) – and preplated in a 10cm Petri dish (Falcon
Primaria, Becton-Dickinson, Etten-Leur, The Netherlands) at 371C.
The fibroblasts were left to attach for 25min.
The unattached NeRCaMs were collected by careful shaking of
the plates. The myocyte cell suspension was divided over six- or
24-well plates with a final cell density of 5 10
4cellcm
 2. Neonatal
rat cardiac myocytes were left to attach for 5–7h. Thereafter, the
preplating medium was refreshed with culture medium consisting
of equal portions of Dulbecco’s modified Eagle’s medium (DMEM,
Life Technologies) and Ham’s F-10 and containing 100Uml
 1
penicillin, 100mgml
 1 streptomycin and 5% HS. Cells were
incubated at 371C in humidified air containing 5% CO2. These
cultures contained at least 90% of synchronously beating
NeRCaMs. The medium was refreshed after 24h. At 48h thereafter,
NeRCaMs cultures were ready for use.
In vitro gene transfer and catalase activity and content
determination
Neonatal rat cardiac myocytes cultured in six-well plates were
incubated with different MOIs (25, 50 and 75) of AdCat in growth
medium (1mlwell
 1)a t3 7
oC. At 2h postinfection, another volume
of virus-free growth medium was added. Control cells were
infected with adenovirus encoding an unrelated protein (MOI 75).
The cells were lysed 24, 48 and 72h postinfection with Ripa
buffer (50mM tris-HCl, 150mM NaCl, 0.1% SDS, 0.5% sodium
deoxycholate (DOC, Fluka Biochemika, Buchs, Switzerland) and
1% nonidet P40 (NP40, Fluka Biochemika)). The cellular lysates
were immediately placed on ice for catalase activity determination
and the remaining lysates were kept at –801C for Western blot
analysis.
The catalase activity was measured by the H2O2 degradation
assay (Aebi, 1984). In brief, 30ml of cellular lysate was mixed with
1ml of TPH buffer (containing 0.02% triton X-100 (Backer,
Deventer, The Netherlands) and 0.03% H2O2 (Backer) in
phosphate buffer (50mM, pH 7.0)) in a quartz cuvette. The
decrease in absorbance (H2O2 degradation) was followed at a
wavelength of 240nm for 30s. The catalase activity was calculated
by interpolating the rate of H2O2 degradation (DAmin
 1) of each
test sample on the calibration curve obtained by plotting the
DAmin
 1 against the catalase activity of the calibration samples
(freshly prepared on the day of analysis).
For the determination of the catalase content, 50mg protein of
each sample (determined by Biorad total protein assay (Bio-Rad
Laboratories B.V., Veenendaal, The Netherlands) was separated on
a 12.5% SDS–PAGE. Thereafter, the proteins were blotted on
Immobilon membrane (Millipore B.V., Etten-Leur, The Nether-
lands). The membrane was rinsed in blocking solution containing
5% nonfat milk, 0.2% Tween 20, 150mM NaCl and 10mM Tris-HCl,
pH 8. Subsequently, catalase protein was immunoprobed with
sheep anti-human catalase 1
ryantibody (1:500 dilution) (The
Binding Site, Birmingham, UK). The blot was incubated with
peroxidase-conjugated donkey anti-sheep IgG 2
ry antibody (Jack-
son Immuno Research Laboratories Incorporation, West Grove,
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sUSA) (1:1000 dilution). For the chemiluminescence detection, the
blot was immersed in 0.025% luminol solution containing 0.01%
H2O2 and exposed to hyperfilm (Kodak London, UK).
MTT (3-(4,-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay and LDH release
The cells grown in 24-well plates were divided into three groups
(see study design in Figure 1A). In one group the cells were
infected with AdCat. At 3days postinfection, the cells were treated
with different concentrations of doxorubicin (0–50mM). In
parallel, the other two groups of noninfected NeRCaMs were
treated with doxorubicin (0–50mM) alone or with 1mM monoHER
(solubilised with 0.5% DMSO). In all, 0.5% of DMSO did not show
any effect on the viability or LDH release from treated cells
compared to the blank. At 24 and 48h after doxorubicin treatment,
the medium was collected for LDH measurement and the cells were
washed with phosphate-buffered saline for the MTT assay.
The LDH activity was measured (Moldeus et al, 1978) by mixing
10ml of the medium with 10ml of a 50mM sodium pyruvate (Merck,
Amsterdam, The Netherlands) solution in 1ml TEA buffer
(containing 500mM triethanolamine, 100mM MgCl2,5 0m M EDTA
and 0.2mM NADH (Sigma Aldrich Chemie, Zwijndrecht, The
Netherlands)). The rate of NADH oxidation was followed at a
wavelength of 340nm. The percentage LDH release in the medium
was plotted against the doxorubicin concentration (taking the
blank as 0% release).
The MTT assay was performed according to Mosmann (1983)
with minor modifications. The percentage survival (taking the
blank as 100% survival) was plotted as a function of the
doxorubicin concentration.
Beating rate measurement
Three groups of cells were assigned for the beating rate
measurement (see study design in Figure 1B). The first group
was infected with AdCat followed by doxorubicin treatment (0–
100mM) 3 days postinfection. The other groups were treated with
different concentrations of doxorubicin (0–100mM) with or
without 1mM monoHER (solubilised with 0.5% DMSO). In all,
0.5% DMSO alone did not affect the beating rate of treated cells
compared to the blank. The mean beating rate of treated cells was
manually counted in two fixed spots per well within 72h after
doxorubicin treatment. During counting, the CO2 atmosphere and
temperature around the cells were kept comparable to that in the
incubator by sealing the plates with parafilm and placing them on
a transparent thermostat box (39
oC) placed over the microscope’s
stage. The temperature in the medium was about 341Ca s
calibrated before the start of the experiment. Under these
conditions, the beating rate was stable for at least 30min.
In order to validate the manual counts, the beating of the cells
was recorded on sVHS tapes through a phase contrast inverted
microscope connected to a video camera. Sequences of beating
images were saved as AVI-files using the Studio DC10plus program
(Pinnacle Systems) with a frame rate of 25Hz. A computer
program was developed for the analysis of beating images and the
calculation of the beating rate of the moving NeRCaMs.
The percentage of beating rate (the value of the beating rate of
treated cells at a certain time 100/the beating rate of the same
cells at zero time) was plotted against time (h).
Statistical analysis
The increase in the total catalase activity in NeRCaMs infected with
AdCat (different MOIs) was statistically evaluated by ANOVA for
the multiple regression of catalase activity on AdCat MOI and days
after infection. In addition, Student’s t-test was used to evaluate
the activity of catalase in cells infected with different MOIs of
AdCat compared with the blank or the control infection at the
respective day.
The change in the LDH release or survival of NeRCaMs treated
with different concentrations of doxorubicin alone, with 1mM
monoHER or with AdCat infection was statistically evaluated by
the ANOVA for multiple regression of ln (viability or LDH release)
on ln doxorubicin concentration alone, with 1mM monoHER or
with AdCat (MOI 25) infection. For the beating rate, the change
was evaluated by the ANOVA for the multiple regression of ln %
beating rate on ln time for each concentration of doxorubicin
alone, with monoHER or with AdCat preinfection.
RESULTS
Catalase activity and content
The activity and content of catalase in NeRCaMs infected with
different MOIs (25, 50 and 75) of AdCat are shown in Figure 2. No
significant increase in the catalase activity in NeRCaMs was
observed after control infection compared to untreated cells
(blank, Po0.485) up to 72h postinfection. Catalase activity
significantly increased at the third day of AdCat infection (with
different MOIs) compared to the blank (Po0.03) and to the
control (Po0.05). No significant difference was observed between
the catalase activity in NeRCaMs infected with different MOIs of
AdCat 3 days postinfection. Cytopathic effects (CPE, cell rounding
up and increased acidity of the medium) limited the use of an MOI
of 450 at the third day postinfection.
The Western blot of catalase confirms the activity measurements
and specifically shows a considerable MOI- and time-dependent
increase in the expression of catalase in cells infected with different
MOIs of AdCat within 3 days postinfection.
AdCat (MOI 50)
Group 1
Group 2,3
Dox (0−50 M) alone
Dox (0−50 M) ± 1mM monoHER
A
24 h
48 h
24 h
48 h
MTT assay
LDH release in the medium
AdCat (MOI 50)
Group 1
Group 2,3
Dox (0−100 M) alone
Dox (0−100 M) ± 1mM monoHER
B
24 48 72 h 30 039
24 48 72 h 30 039
3 days
Beating rate measurements
3 days
Figure 1 Schematic presentation of the study design.
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sSurvival and LDH release
Figures 3 and 4 show the survival of NeRCaMs and the LDH release
24 and 48h after treatment with different concentrations of
doxorubicin with or without preinfection with AdCat (MOI 50) or
cotreatment with 1mM monoHER (MH). Doxorubicin caused
cytotoxic effects in NeRCaMs. A significant concentration-
dependent reduction in the percentage of surviving NeRCaMs
was observed within 48h after treatment (Po0.0005). Cell death
was, as expected, accompanied by a significant increase in the LDH
release in the medium of doxorubicin-treated cells (Po0.0005).
No cytotoxic effects (reduced viability or increased LDH release)
were observed after infection with AdCat (MOI 50) during 5 days
after infection. A 3.5-fold increase in the activity of AdCat did not
protect against doxorubicin-induced reduction in the survival of
NeRCaMs or the associated increase in the LDH release from the
myocytes within 48h after doxorubicin treatment.
On the other hand, 1mM monoHER alone had no influence on
the viability or LDH release from treated NeRCaMs during 48h
after treatment. 7-Monohydroxyethylrutoside significantly pro-
tected against the lethal effect of doxorubicin on the survival of
NeRCaMs during 48h after doxorubicin treatment (Po0.0005). 7-
Monohydroxyethylrutoside also significantly decreased doxorubi-
cin-induced LDH release from NeRCaMs 48h after doxorubicin
treatment (P¼0.004).
Beating rate
The beating rate of NeRCaMs within 3 days after treatment with
different concentrations of doxorubicin with or without preinfec-
tion with AdCat (MOI 50) or cotreatment with 1mM monoHER is
shown in Figure 5. The beating rate of untreated cells (blank) was
relatively stable during the course of the experiment and was
109723bpm. Infection with AdCat (MOI 50) or treatment with
1m M monoHER alone did not significantly influence the beating
rate of NeRCaMs compared to the blank.
Doxorubicin significantly decreased the beating rate of NeR-
CaMs in a concentration- and time-dependent manner
(Po0.0005). The time at which cells stopped beating (tzero) after
different treatments is summarised in Table 1. The tzero was
inversely proportional to the doxorubicin concentration and
ranged from 72 to 9h after treatment with 10 and 100mM
doxorubicin, respectively.
Infection with AdCat (MOI 50) did not protect against the
negative chronotropic effect of doxorubicin on NeRCaMs during
72h after doxorubicin treatment (Table 1, Figure 5). Cotreatment
with 1mM monoHER significantly protected against doxorubicin-
induced reduction of the beating rate of NeRCaMs (Po0.0005). 7-
Monohydroxyethylrutoside prolonged the tzero for 472h even in
the presence of high concentrations (50, 100mM) of doxorubicin
(Table 1, Figure 5).
DISCUSSION
Enhancing the low antioxidant capacity of heart tissue was the
rationale behind several studies conducted for the protection
against doxorubicin-induced cardiotoxicity (Keizer et al, 1990).
This cardiotoxicity has mainly been attributed to the production of
free radicals. Doxorubicin can generate free radicals in different
ways. It can be enzymatically and nonenzymatically reduced to the
semiquinone form (Goeptar et al, 1993, 1994). In the presence of
oxygen, the semiquinone form donates the extra electron to
molecular oxygen producing superoxide anion radical (O2
K ).
Spontaneous or enzymatic dismutation of two molecules of O2
K 
produces H2O2. Hydrogen peroxide can also be produced by redox
cycling of doxorubicin after complexation with iron cations
(Sterrenberg et al, 1984; Minotti, 1989). Hydrogen peroxide can
be converted into hydroxyl radicals, through Fenton reaction (Yu
and Anderson, 1997), which are much more toxic than O2
K .
In a previous study using a superoxide dismutase (CuZn-sod)-
encoding adenovirus (AdCuZn-sod), we have shown that moderate
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s.e.m. The P-values (* compared to blank Po 0.03 and x compared to the
control Po 0.05), which indicate significant increase in the catalase activity,
were calculated by Student’s t-test.
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Figure 3 Protective effect of preinfection with AdCat (MOI 50) or
cotreatment with 1mM monoHER against doxorubicin-induced LDH
release (A) and survival (B) of NeRCaMs 1 day after doxorubicin
treatment. Values are mean (n¼3) 7 s.e.m. The P-values, which indicate
significant protection against doxorubicin damage, were calculated by the
ANOVA of multiple regression of ln (survival or LDH release) vs ln
doxorubicin concentration alone, with 1mM monoHER or with AdCat
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soverexpression of CuZn-sod did not protect against doxorubicin-
induced cardiotoxicity in cultured cardiac myocytes (Abou El
Hassan, 2003).
Even more, the AdCuZn-sod induced cytotoxicity at a relatively
low MOI of more than 25 virus infectious units per cell. This
cytotoxicity might be caused by the viral vector or by CuZn-sod
itself because its conversion of the doxorubicin-produced O2
K  into
H2O2 in the presence of low levels of catalase would cause
accumulation of H2O2, which is subsequently converted into
hydroxyl radicals, which are much more reactive than O2
K  radicals
in inducing cellular damage. This implies that the overexpression
of CuZn-sod in cells harbouring low levels of catalase, such as
cardiac myocytes, would cause damage rather than protection of
these cells, which is supported by the data of Xing et al (2002) and
Midorikawa and Kawanishi (2001).
Catalase is responsible for converting H2O2 to water and oxygen
(Deshmukh et al, 1997). The level of catalase in heart tissue
presents only 2% of that in the liver in different species (Doroshow
et al, 1980; Ishikawa et al, 1986; Chen et al, 1994), which allows the
conversion of undetoxified H2O2 into hydroxy radicals (OH
K)a s
mentioned previously.
Various degrees of effect on myocardial cells have been observed
using exogenous catalase to protect against free radical damage
(Gross et al, 1986; Przyklenk and Kloner, 1986; Jeroudi et al, 1990).
Actually, some reports demonstrated no protection at all in vivo
(Bjorkman et al, 1991; Villani et al, 1992). These conflicting results
were attributed to several limiting factors among which the short
half-life and rapid clearance of the exogenously administered
catalase were regarded as the main hurdles. Another factor is the
poor endocytosis of exogenous catalase by cardiac myocytes
(Chudej et al, 1990), which suggests a limited penetration of
catalase into doxorubicin-treated cells and thereby limits the
protective effect of catalase.
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significant protection against doxorubicin damage, were calculated by the
ANOVA of multiple regression of ln (survival or LDH release) vs ln
doxorubicin concentration alone, with 1mM monoHER or with AdCat
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Figure 5 Beating rate of NeRCaMs within 3 days of treatment with different concentrations of doxorubicin (–~– ) with(out) preinfection with AdCat
(MOI 50) (?B?) or cotreatment with 1mM monoHER (–B–). The P-values, which indicate significant protection against doxorubicin effect, were
calculated by the ANOVA of multiple regression of ln (beating rate) vs ln doxorubicin concentration alone, with 1mM monoHER or with AdCat (MOI 50)
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Table 1 Tzero of NeRCaMs treated with different concentrations of
doxorubicin (10–100mM) with or without 1mM monoHER or preinfection
with AdCat (MOI¼50). Values are mean (n¼3) 7s.e.m.
Dox
Tzero (h)
lM Dox Dox + AdCat Dox + MH
10 72.070.0 72.070.0 472
25 42.076.0 48.070.0 472
50 26.072.0 24.070.0 472
100 9.070.0 7.072.0 472
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sThese limitations were circumvented by using transgenic mice
overexpressing catalase. Several studies have been undertaken to
investigate the susceptibility of these animals to free radical
producing treatments (e.g. doxorubicin and IR). A 60-fold increase
in catalase activity protected against the decrease in contractile
force and morphological changes induced by hypoxia reoxygena-
tion (H/R) (Chen et al, 1997). In another study, a high increase in
catalase (60-fold) promoted the recovery of the contractile
function of isolated hearts and to protect against creatine kinase
CK efflux (Li et al, 1997).
A 60–100-fold increase in catalase expression protected against
the increase in lipid peroxidation and plasma CPK in doxorubicin-
treated transgenic mice, while lower or higher increases (15- and
200-fold, respectively) did not (James Kang et al, 1996). This study
illustrates a bell-shape protective effect of catalase.
The present study was designed to increase the level of catalase
alone while maintaining the endogenous levels of catalase aiming
to overcome hydroxyl radical damage. Significant levels of catalase
were produced in NeRCaMs at the third day of AdCat infection
compared to mock-infected cells. However, the occurrence of
cellular cytotoxicity limited the MOI of AdCat to 50pfucell
 1,
which only produced a 3.5-fold increase in the activity of catalase
in infected cells at the third day of infection compared to blank.
This may explain why the 3.5-fold increase in the level of catalase
did not protect against doxorubicin cardiotoxicity. Others showed
that a nine-fold increase in catalase level in vascular endothelial
cells (HUVECs) in vitro could protect against the damage induced
by 0.5 but not by 1mM H2O2 (Erzurum et al, 1993). In another
study, a five-fold increase in catalase activity after lung gene
transfer of catalase did not protect against ischemia perfusion-
induced free radical in an isolated perfused lung model (Danel et al,
1998). Therefore, it is clear from the different studies that surplus
amount of catalase should be achieved to counteract the burst of
radicals produced by doxorubicin. The expression level of catalase
produced by the present AdCat cannot be induced further since
expression of the catalase gene is driven by the major late
promoter of adenovirus 2, which is known to be among the
strongest promoters available.
Doxorubicin alone decreased the viability of NeRCaMs in a
concentration-dependent manner. This decrease was accompanied
by an increase in the LDH release from treated cells. This is in line
with previous reports, which showed that the free radicals
produced by doxorubicin interact with the phospholipids of the
cell membrane and produce membrane damage (Sterrenberg et al,
1984).
It is remarkable that when all the cells completely stopped
beating, a fair fraction (10–16%) was still viable. This indicates
that high energy demanding processes like beating stops before the
complete death of cells. This probably resulted from a doxor-
ubicin-induced reduction of cellular ATP levels (Cini Neri et al,
1991).
Recently, the beneficial effects of flavonoids have been shown in
the treatment of different diseases (Wagner, 1985). Among them
monoHER, in contrast to catalase, significantly protected against
doxorubicin cytotoxic effects (Survival, LDH release and beating
rate). The pronounced protection of monoHER was most probably
caused by its site-specific action as a potent antioxidant and a
metal ion chelator (Van Acker et al, 1996, 1998). 7-Monohydrox-
yethylrutoside may also be a good protector against membrane
damage because it is one of the constituents of the flavonoid
mixture Venorotun
s that is used in the treatment of chronic
venous insufficiency presumably via the stabilisation of collagen
(Wagner, 1985). The combination of these properties makes
monoHER a powerful protector against doxorubicin-induced
cardiotoxicity.
In conclusion, the present study shows that a 3.5-fold increase in
the level of catalase in cultured NeRCaMs was not enough to
protect against doxorubicin-induced cardiotoxicity. In contrast,
monoHER protected NeRCaMs against doxorubicin-induced
membrane damage (as illustrated by the increase in the LDH
release from treated cells) and decrease in viability of treated cells.
7- Monohydroxyethylrutoside also protected against the negative
chronotropic action of doxorubicin on cardiac myocytes, which is
in agreement with the cardioprotecting effects of monoHER
described earlier (Van Acker SABE et al, 1997; Van Acker FAA
et al, 2000).
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